Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.00
-0.28 (-3.02%)
Jun 27, 2025, 4:00 PM - Market closed
Zevra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 40.59 | 23.61 | 27.46 | 10.16 | 28.65 | 13.29 | Upgrade
| |
Revenue Growth (YoY) | 46.47% | -14.02% | 170.26% | -64.53% | 115.61% | 3.50% | Upgrade
|
Cost of Revenue | 8.59 | 7.42 | 2.17 | 0.22 | 2.06 | 1.31 | Upgrade
|
Gross Profit | 32 | 16.2 | 25.29 | 9.94 | 26.59 | 11.98 | Upgrade
|
Selling, General & Admin | 64.53 | 54.92 | 35.09 | 15.61 | 9.23 | 8.44 | Upgrade
|
Research & Development | 33.03 | 42.04 | 39.03 | 19.23 | 9.64 | 8.32 | Upgrade
|
Operating Expenses | 103.88 | 103.2 | 74.89 | 34.84 | 18.86 | 16.76 | Upgrade
|
Operating Income | -71.88 | -87 | -49.6 | -24.9 | 7.73 | -4.78 | Upgrade
|
Interest Expense | -8.59 | -7.35 | -1.5 | -0.34 | -0.38 | -7.09 | Upgrade
|
Interest & Investment Income | 1.79 | 2.18 | 4.54 | 1.51 | 0.26 | 0.09 | Upgrade
|
Other Non Operating Income (Expenses) | 3.3 | 2.06 | -0.1 | 15.16 | -0.03 | -0.18 | Upgrade
|
EBT Excluding Unusual Items | -75.37 | -90.12 | -46.66 | -8.57 | 7.59 | -11.97 | Upgrade
|
Merger & Restructuring Charges | - | - | - | - | - | -0.83 | Upgrade
|
Gain (Loss) on Sale of Investments | 0.01 | -0.02 | 0.61 | -0.58 | -0.01 | - | Upgrade
|
Other Unusual Items | - | - | - | - | -16.1 | - | Upgrade
|
Pretax Income | -75.37 | -90.14 | -46.05 | -26.81 | -8.52 | -12.79 | Upgrade
|
Income Tax Expense | 16.62 | 15.37 | - | -0.03 | 0.03 | -0.03 | Upgrade
|
Net Income | -91.99 | -105.51 | -46.05 | -26.77 | -8.56 | -12.76 | Upgrade
|
Preferred Dividends & Other Adjustments | - | - | - | - | 54.34 | - | Upgrade
|
Net Income to Common | -91.99 | -105.51 | -46.05 | -26.77 | -62.9 | -12.76 | Upgrade
|
Shares Outstanding (Basic) | 49 | 46 | 35 | 34 | 30 | 4 | Upgrade
|
Shares Outstanding (Diluted) | 49 | 46 | 35 | 34 | 30 | 4 | Upgrade
|
Shares Change (YoY) | 32.32% | 30.46% | 2.79% | 15.87% | 647.72% | 114.79% | Upgrade
|
EPS (Basic) | -1.86 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | Upgrade
|
EPS (Diluted) | -1.86 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | Upgrade
|
Free Cash Flow | -61.82 | -69.67 | -33.83 | -18.81 | 10.34 | -1.97 | Upgrade
|
Free Cash Flow Per Share | -1.25 | -1.51 | -0.95 | -0.55 | 0.35 | -0.49 | Upgrade
|
Gross Margin | 78.84% | 68.59% | 92.09% | 97.81% | 92.81% | 90.18% | Upgrade
|
Operating Margin | -177.09% | -368.47% | -180.63% | -245.07% | 26.98% | -35.98% | Upgrade
|
Profit Margin | -226.64% | -446.85% | -167.69% | -263.48% | -219.54% | -96.03% | Upgrade
|
Free Cash Flow Margin | -152.31% | -295.04% | -123.20% | -185.12% | 36.08% | -14.84% | Upgrade
|
EBITDA | -65.4 | -80.61 | -48.6 | -23.96 | 7.99 | -4.51 | Upgrade
|
EBITDA Margin | -161.14% | - | -176.97% | -235.78% | 27.87% | -33.92% | Upgrade
|
D&A For EBITDA | 6.48 | 6.39 | 1.01 | 0.94 | 0.26 | 0.27 | Upgrade
|
EBIT | -71.88 | -87 | -49.6 | -24.9 | 7.73 | -4.78 | Upgrade
|
EBIT Margin | -177.09% | - | -180.63% | -245.07% | 26.98% | -35.98% | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.